Intravacc and Primrose Bio Renew Partnership to Expand End-to-End Conjugate Vaccine GMP Capabilities

For CDMOs and vaccine developers navigating conjugate program scale-up, Intravacc and Primrose Bio have renewed their strategic partnership, consolidating carrier protein supply, conjugation process development, and GMP production under a single integrated offering. The renewal, announced June 1, positions third-party clients to access a continuous development-to-manufacturing pathway without sourcing carrier protein and conjugation expertise from separate vendors.

The arrangement pairs Intravacc's antigen conjugation process development, scale-up, and GMP manufacturing capabilities with Primrose Bio's PeliCRM197® carrier protein, described by the companies as the only CRM197 used in commercial vaccines that is available for open purchase. PeliCRM197® is supplied across research and GMP grades, from milligram to kilogram quantities, giving early-stage programs a single material source that can scale through clinical production without a supplier transition.

For QA directors and regulatory leads managing conjugate vaccine programs, the practical implication is reduced supplier qualification burden. A single-source solution spanning carrier protein supply chain, regulatory documentation support, and GMP conjugation manufacturing compresses the vendor management overhead that typically accumulates across preclinical-to-Phase I/II transitions. Primrose Bio was established in 2023 from the merger of Primordial Genetics and Ligand Pharmaceuticals' Pfenex Expression Technology® platform, bringing established commercial references including Merck, Serum Institute of India, and Jazz Pharmaceuticals.

Intravacc's contribution centers on its bacterial and cell-culture conjugation platforms and its track record in technology transfer to GMP-compliant production. The Bilthoven-based CDMO supports programs from early-stage research through Phase I/II clinical production, a scope that aligns directly with the gap both companies identify: early-stage conjugate vaccine clients requiring integrated development support without assembling a fragmented supply chain.

The measurable outcome for clients will be how efficiently programs transition from conjugation process development into GMP lot production under a single contractual and quality framework.

Source: Intravacc and Primrose Bio via GlobeNewswire, June 1, 2026.